NSIX -- Neuromedical Systems, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NSIX -- Neuromedical Systems, Inc.

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: notrich who wrote ()	7/25/1996 5:03:00 PM
From: Allen Sansano	of 137

I don't follow NSIX that much but I do follow Neopath (NPTH) who is the other company in this business. Currently NSIX and NPTH have QC machines that check the slides after they have already been checked by a qualified technician. The big money is if they can automate the whole process including the primary screening. NSIX recently filed a lawsuit against NPTH claiming patent infringement and unfair marketing practives. As far as I understand they both are making headway in getting their QC machines into the labs. They use differt technology to do the same thing. I think NSIX uses neural network type algorithms and NPTH uses raw image processing. Neopath recently announced they had filed with the FDA for PMA on the use of their systems for primary screening. Along with this filing came a nice rise in their stock of about 4 points to $24. A ruling is expected end of Sept (29th?). I expect NSIX should announce somthing similar soon. They both had rulings on their PMA for the QC systems within days of each other. The technology for the QC systems is similar as that for the primary screening systems. It's just that there is more riding on the primary line systems so approval is more complicated and takes longer. The market for these systems is potentially huge. I think Neopath has a pay-per-use system for the QC running something like $4 per slide which is tagged on to the cost of the screen. The overall cost of a screen is partially offset by not having to do the manual rescreen. It is recommended that all women get a PAP smear annually. Of course they all don't, but $4 times the number of women in this world is a huge potentially market. And this is just for rescreening. Let's assume 2 billions women need PAP smears and that just 10% get them done by machine. Now let's say you pay $4 for the complete test done by machine, same as current rescreening. This is an $800M/year industry!! This is not a completely detailed analysis of the potential market but you get the picture. Comments? -Allen

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext